Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Aurora Cancer Care-Southern Lakes VLCC
mi
from
Burlington, WI
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Aurora Cancer Care-Southern Lakes VLCC
mi
from
Burlington, WI
Click here to add this to my saved trials
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Aurora Health Care Germantown Health Center
mi
from
Germantown, WI
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Aurora Health Care Germantown Health Center
mi
from
Germantown, WI
Click here to add this to my saved trials
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Saint Mary's
mi
from
Green Bay, WI
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Saint Mary's
mi
from
Green Bay, WI
Click here to add this to my saved trials
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Aurora Saint Lukes Medical Center
mi
from
Milwaukee, WI
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Aurora Saint Lukes Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated:  12/31/1969
HSHS Saint Nicholas Hospital
mi
from
Sheboygan, WI
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated: 12/31/1969
HSHS Saint Nicholas Hospital
mi
from
Sheboygan, WI
Click here to add this to my saved trials
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Aurora Bay Area Medical Group-Marinette
mi
from
Marinette, WI
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Aurora Bay Area Medical Group-Marinette
mi
from
Marinette, WI
Click here to add this to my saved trials
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated:  12/31/1969
House Reserach Institute
mi
from
Los Angeles, CA
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated: 12/31/1969
House Reserach Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated:  12/31/1969
New York Univ. Medical Center
mi
from
New York, NY
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated: 12/31/1969
New York Univ. Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated:  12/31/1969
Weil Cornell Medical College, New York Presbyterian Hospital
mi
from
New York, NY
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated: 12/31/1969
Weil Cornell Medical College, New York Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated:  12/31/1969
Washington University Medical Center
mi
from
Saint Louis, MO
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas
Status: Enrolling
Updated: 12/31/1969
Washington University Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Identification and Treatment of Depression
Identification and Treatment of Depression in Underserved African American and Latino Patients With Cancer
Status: Enrolling
Updated:  12/31/1969
LBJ General Hospital
mi
from
Houston, TX
Identification and Treatment of Depression
Identification and Treatment of Depression in Underserved African American and Latino Patients With Cancer
Status: Enrolling
Updated: 12/31/1969
LBJ General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Ocala Oncology Center
mi
from
Ocala, FL
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of Florida
mi
from
Ocoee, FL
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of Florida
mi
from
Ocoee, FL
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of North Carolina
mi
from
Raleigh, NC
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of North Carolina
mi
from
Raleigh, NC
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Arlington South
mi
from
Arlington, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Arlington South
mi
from
Arlington, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Willamette Valley Cancer Institute/Research Ctr
mi
from
Eugene, OR
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Willamette Valley Cancer Institute/Research Ctr
mi
from
Eugene, OR
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Yakima Valley Mem Hosp/North Star Lodge
mi
from
Yakima, WA
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Yakima Valley Mem Hosp/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors
Study of Automated Abdominal Compression Device and Screw Based Abdominal Compression Devices During Stereotactic Body Radiation Therapy of Lung Tumors
Status: Enrolling
Updated:  12/31/1969
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors
Study of Automated Abdominal Compression Device and Screw Based Abdominal Compression Devices During Stereotactic Body Radiation Therapy of Lung Tumors
Status: Enrolling
Updated: 12/31/1969
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine
A Pilot Study of Pioglitazone as Second Line Therapy for Patients With Previously Treated Metastatic Adenocarcinoma of the Pancreas With Disease Progression After Gemcitabine Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine
A Pilot Study of Pioglitazone as Second Line Therapy for Patients With Previously Treated Metastatic Adenocarcinoma of the Pancreas With Disease Progression After Gemcitabine Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute Pediatric Oncology Branch
mi
from
Bethesda, MD
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute Pediatric Oncology Branch
mi
from
Bethesda, MD
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Pediatric Brain Tumor Consortium
mi
from
Memphis, TN
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Pediatric Brain Tumor Consortium
mi
from
Memphis, TN
Click here to add this to my saved trials
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated:  12/31/1969
Childrens National Medical Center
mi
from
Washington,
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System
Status: Enrolling
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia
Phase II Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (AML-TLD)
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia
Phase II Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (AML-TLD)
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
A Phase I, Non-randomized, Multiple Dose, Dose Escalation Study of the Safety, PK, PD and Efficacy of Therapeutic Vaccine, BP-GMAX-CD1, Plus Activating Agent, AP1903, in Patients With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center Houston, CRU
mi
from
Houston, TX
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
A Phase I, Non-randomized, Multiple Dose, Dose Escalation Study of the Safety, PK, PD and Efficacy of Therapeutic Vaccine, BP-GMAX-CD1, Plus Activating Agent, AP1903, in Patients With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center Houston, CRU
mi
from
Houston, TX
Click here to add this to my saved trials